Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia, stemming from defects in insulin secretion, insulin action, or both. The disorder is categorized into two primary types: Type 1 diabetes (T1D), an autoimmune condition resulting in the destruction of insulin-producing pancreatic beta cells, and Type 2 diabetes (T2D), characterized by insulin resistance and impaired insulin secretion. Chronic hyperglycemia is associated with severe complications, including cardiovascular and neurological disorders, while hypoglycemia can result in life-threatening conditions such as unconsciousness or death. Traditional diabetes management strategies, particularly for T1D and progressive T2D, often involve frequent insulin injections and regular blood glucose monitoring. These methods are invasive and pose challenges related to patient compliance and precise glycemic control. Nanotechnology has emerged as a promising frontier in diabetes management, offering innovative approaches to drug delivery and glucose monitoring. Nanomaterials, including silica nanoparticles, solid lipid nanoparticles (SLNs), quantum dots (QDs), polymeric nanoparticles, and carbon-based materials like graphene oxide (GO) and carbon nanotubes (CNTs), provide enhanced drug bioavailability, stability, targeted delivery, and improved patient compliance. Moreover, nanotechnology-enabled biosensors and continuous glucose monitoring systems utilizing nanosensors and quantum dots enhance the sensitivity and specificity of glucose detection, enabling real-time monitoring and early diagnosis of diabetes-related complications. The application of nanoparticles in conjunction with phytochemicals also shows potential for managing MS and diabetes, highlighting the multifaceted benefits. This chapter delves into the role of nanomaterials in diabetes management, exploring their potential to revolutionize treatment protocols and improve outcomes for diabetic patients.